Latest Ratios: P/E Ratio -121.0x · EV/EBITDA N/A · ROE -38.4%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.5B | $1.6B | $726M | $54M | $24M | $243M | $344M | $561M | $190M | — | — |
| Enterprise Value | $3.5B | $1.5B | $705M | $-78144401 | $9M | $112M | $286M | $496M | $132M | — | — |
| P/E Ratio → | -121.03 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1289.98 | 764.98 | 116.48 | 18.97 | 3.69 | 164.92 | — | — | — | — | — |
| P/B Ratio | 6.43 | 3.16 | 2.06 | 0.32 | 0.32 | 1.41 | 2.39 | 3.97 | 1.30 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 740.57 | 113.06 | -27.65 | 1.42 | 75.73 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -8739.3% | -8739.3% | -1633.7% | -1704.7% | -462.9% | -886.6% | — | — | — | — | — |
| Net Profit Margin | -7973.3% | -7973.3% | -1362.8% | -1541.2% | -443.8% | -888.1% | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -38.4% | -38.4% | -32.6% | -35.9% | -23.1% | -8.3% | -52.6% | -53.5% | -58.7% | -119.6% | -104.3% |
| ROA | -35.9% | -35.9% | -30.7% | -33.2% | -20.9% | -7.5% | -46.4% | -48.2% | -54.3% | -107.9% | -83.2% |
| ROIC | -34.4% | -34.4% | -41.5% | -75.1% | -44.5% | -15.5% | -72.9% | -76.2% | -104.5% | -1647.4% | — |
| ROCE | -41.6% | -41.6% | -38.8% | -39.4% | -23.4% | -7.9% | -52.9% | -56.4% | -60.8% | -120.4% | -102.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.10 | -0.06 | -0.78 | -0.20 | -0.76 | -0.40 | -0.46 | -0.40 | -1.02 | -0.50 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -19.90 | — | — | — | -56.86 |
Net cash position: cash ($51M) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.32 | 13.32 | 15.22 | 18.42 | 9.97 | 16.63 | 13.26 | 10.62 | 13.95 | 12.68 | 4.71 |
| Quick Ratio | 13.32 | 13.32 | 15.22 | 18.42 | 9.97 | 16.63 | 13.26 | 10.62 | 13.95 | 12.68 | 4.71 |
| Cash Ratio | 13.16 | 13.16 | 14.92 | 18.04 | 9.18 | 16.29 | 13.02 | 10.32 | 13.68 | 12.45 | 1.98 |
| Asset Turnover | — | 0.00 | 0.02 | 0.02 | 0.08 | 0.01 | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 18.29 | 47.24 | 61.74 | 320.69 | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $38M | $33M | $5M | $4M | $3M | $3M | $2M | $2M | $2M | $2M |
Includes 30+ ratios · 10 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DNTH stock.
Dianthus Therapeutics, Inc.'s current P/E ratio is -121.0x. This places it at the 50th percentile of its historical range.
Dianthus Therapeutics, Inc.'s return on equity (ROE) is -38.4%. The historical average is -52.7%.
Based on historical data, Dianthus Therapeutics, Inc. is trading at a P/E of -121.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Dianthus Therapeutics, Inc. has 100.0% gross margin and -8739.3% operating margin.
Key Metrics
Top Statement Risk
Cash runway shortfall and dilution
Metrics are mathematically derived from official filings.
Multiples Distorted by Pre-Commercial Earnings
Based on reported figures, DNTH trades at a P/E of -123.98 and a P/S of 1321.47, multiples that are mathematically meaningless against near-zero earnings and a $2.04M TTM revenue base, making the price-to-book of 6.59 the more informative anchor.
The negative P/E and extreme P/S reflect a market price anchored to the clinical pipeline rather than to any earnings or sales stream, so these multiples should be treated as non-diagnostic. The P/B of 6.59 compared with peers such as IMVT at 6.53 and ALXO at 2.40 suggests DNTH is priced in line with or above similarly staged competitors on book value. Investors should monitor whether this premium is justified by DNTH103 probability-adjusted value rather than balance-sheet support, since book value here is largely a product of recent equity raises.
Minimal Debt Keeps Solvency Risk Low
According to recent SEC filings, DNTH carried roughly $1.2M of total debt at 2026Q3 against a D/E ratio near 0.00, a leverage profile that is effectively unlevered and sits well below peer ratios of 0.20 for ALXO and 0.18 for RCUS.
Interest coverage and D/EBITDA cannot be meaningfully computed because operating income is deeply negative, so traditional debt-service metrics provide no comfort or warning. The low absolute debt load means covenant and refinancing risk is limited, which shifts the solvency question entirely toward equity funding capacity. This may indicate that financing risk is a dilution question rather than a creditor question, and investors should monitor the next equity raise timing.
Liquidity Ratios Mask Thin Operating Runway
As reported in the balance sheet, DNTH's current ratio of 30.02 at 2026Q3 looks exceptionally strong, but cash of roughly $51M to $55.7M against quarterly operating outflows near $50M implies a runway potentially under one year.
A current ratio above 30 is driven by a large current asset pool that is dominated by cash and short-term investments relative to minimal current liabilities, not by any durable operating strength. Quick ratio equals current ratio here because inventory is absent, so the test of stress resilience depends solely on cash burn duration. Based on reported figures, if burn persists at present levels, a dilutive financing event may be required well before the liquidity ratio itself deteriorates, which warrants further investigation into management's runway disclosures.
Returns Oscillate Without Compounding Capital
Based on reported figures, DNTH's ROIC swung from -37.9% in 2024Q2 to -5.6% in 2026Q2 and ROE moved between -4.2% and 18.8%, a pattern driven by non-operating items rather than improving operational returns.
The 18.8% ROE in 2025Q4 coincides with a $97.9M net income against a -$69.5M operating loss, indicating the spike is a non-operating gain and not evidence of compounding. Underlying ROIC remains negative across the series, which suggests the company is consuming invested capital rather than earning returns on it. Investors should treat the reported ROE trend with caution and focus on whether operating losses narrow as trial spending matures.
Working Capital Metrics Lack Operational Meaning
As reported in financial statements, DNTH's DSO fluctuated from 62 days in 2024Q2 to 826 days in 2025Q4 on a revenue base that is largely legacy and non-recurring, rendering the cash conversion cycle uninformative.
DSO spikes reflect lumpy collaboration or milestone receivables rather than a steady customer credit cycle, so the efficiency signal is driven by revenue timing rather than collection performance. Inventory, DIO, and the cash conversion cycle are effectively unavailable because the company has no manufactured product, and DPO readings are sparse and volatile. This suggests working capital analysis offers limited insight, and attention should shift to cash burn per quarter instead.
Gross Margin Misleads on Pre-Commercial Economics
Based on reported figures, DNTH's 100% gross margin appears to reflect milestone revenue with no cost of goods sold rather than durable unit economics, while operating margin fell to -244.9% in 2025Q4, obscuring the true cost base.
A 100% gross margin is an accounting artifact of revenue recognized without COGS and should not be used to infer pricing power or commercial scalability. The more relevant metric is the operating loss relative to cash on hand, or quarterly cash burn divided by runway, which better captures the financing need. Modeling should rely on probability-adjusted pipeline value rather than margin-based earnings power, and investors should monitor whether operating expenses scale further with Phase 2 enrollment.